Ostrowitzki, Susanne, Deptula, Dennis, Thurfjell, Lennart, Barkhof, Frederik, Bohrmann, Bernd, Brooks, David J., Klunk, William E., Ashford, Elizabeth, Yoo, Kisook, Xu, Zhi-Xin, Loetscher, Hansruedi, Santarelli, Luca

Background: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD).; Objectives: To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction.; Design: A multicenter, randomized, double-blind, placebo-controlled, ascending-dose […]

Egefjord, Lærke, Gejl, Michael, Møller, Arne, Brændgaard, Hans, Gottrup, Hanne, Antropova, Olga, Møller, Niels, Poulsen, Henrik E., Gjedde, Albert, Brock, Birgitte, Rungby, Jørgen

Introduction: Type 2 diabetes (DM-2) increases the risk of developing Alzheimer´s disease (AD), and patients with AD are more likely to develop DM-2. DM-2 and AD share some pathophysiological features. In AD, amyloid-β (Aβ) is accumulated as extracellular plaques in the gray matter of the brain, while in DM-2 islet amyloid polypeptide (IAPP) is accumulated […]

Dockens, Randy, Wang, Jun-Sheng, Castaneda, Lorna, Sverdlov, Oleksandr, Huang, Shu-Pang, Slemmon, Randy, Gu, Huidong, Wong, Oi, Li, Hewei, Berman, Robert M., Smith, Christina, Albright, Charles F., Tong, Gary

Background and Objectives: Avagacestat is an orally active γ-secretase inhibitor that selectively inhibits amyloid β (Aβ) synthesis in cell culture and animal models. The objective of the current study was to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of avagacestat over 28 days in healthy young men and elderly men and women […]

DiSilvestro, Robert A., Joseph, Elizabeth, Zhao, Shi, Bomser, Joshua

Background: Curcumin extracts of turmeric are proposed to produce health benefits. To date, human intervention studies have focused mainly on people with existing health problems given high doses of poorly absorbed curcumin. The purpose of the current study was to check whether in healthy people, a low dose of a lipidated curcumin extract could alter […]

Endres, Kristina, Fahrenholz, Falk, Lotz, Johannes, Hiemke, Christoph, Teipel, Stefan, Lieb, Klaus, Tüscher, Oliver, Fellgiebel, Andreas

Objective: We investigated induction of α-secretase A disintegrin and metalloprotease 10 (ADAM10) by the synthetic retinoid acitretin (Neotigason; Actavis, München-Riem, Germany) in patients with mild to moderate Alzheimer disease (AD) via measurement of CSF content of α-secretase-derived amyloid precursor protein (APPs-α).; Methods: Twenty-one patients clinically diagnosed with mild to moderate AD received acitretin (30 mg […]

Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., Crans, G., Liang, E., Quinn, G., Bairu, M., Pastrak, A., Cedarbaum, J. M.

Objective: This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD).; Methods: A total of 353 patients were randomized to ELND005 (250, 1,000, or 2,000 mg) or placebo twice daily for 78 weeks. Coprimary endpoints were the […]

Dodel, Richard, Rominger, Axel, Bartenstein, Peter, Barkhof, Frederik, Blennow, Kaj, Förster, Stefan, Winter, Yaroslav, Bach, Jan-Philipp, Popp, Julius, Alferink, Judith, Wiltfang, Jens, Buerger, Katharina, Otto, Markus, Antuono, Piero, Jacoby, Michael, Richter, Ralph, Stevens, James, Melamed, Isaac, Goldstein, Jerome, Haag, Stefan, Wietek, Stefan, Farlow, Martin, Jessen, Frank

Background: Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer’s disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients.; Methods: We did a multicentre, placebo-controlled phase 2 trial at seven sites in the USA and five in Germany. Participants with probable Alzheimer’s […]